{
    "clinical_study": {
        "@rank": "25064", 
        "arm_group": [
            {
                "arm_group_label": "Active rTMS", 
                "arm_group_type": "Active Comparator", 
                "description": "20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the FDA-approved device label (10 Hz) to a targeted area of the brain.  After these sessions, a second fMRI will be completed then 5 additional tapering treatments of rTMS over a 2 week period."
            }, 
            {
                "arm_group_label": "Sham rTMS", 
                "arm_group_type": "Sham Comparator", 
                "description": "20 sham sessions, within a 4 week period, where subjects receive inactive treatments (0 Hz) of repetitive Transcranial Magnetic Stimulation (rTMS).  After 20 sessions and completion of a second fMRI scan, patients in this group will then be unblinded and transitioned to the active arm and will receive a full course (25 sessions) of active rTMS over a 6 week period."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research is to learn more about how rTMS works to reduce the symptoms of\n      depression. This information can be used to improve the effectiveness of the treatment. The\n      study will use functional magnetic resonance imaging (fMRI) to examine changes in brain\n      function after treatment with rTMS.  fMRI is a safe and painless technique that allows\n      investigators to observe the brain \"at work.\" The investigators will use fMRI to see what\n      regions of the brain become active when you perform a concentration task and how that\n      activation is changed after rTMS."
        }, 
        "brief_title": "Imaging Biomarkers for TMS Treatment of Depression", 
        "condition": "Depression", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Primary diagnosis of major depressive disorder\n\n          -  Male and female subjects, ages 22-65\n\n          -  Have failed at least 1 antidepressant medication at adequate dose and duration\n\n          -  On stable antidepressant medication regimen for at least 4 weeks prior to TMS therapy\n\n        Exclusion Criteria:\n\n          -  Diagnosed with a psychotic, bipolar, obsessive-compulsive or post-traumatic stress\n             disorder\n\n          -  Active substance abuse, including alcohol\n\n          -  Medical and/or neurological condition that could affect your brain function or risk\n             of seizure, including a stroke, epilepsy, or a closed head injury;\n\n          -  No presence of an implanted device like a pacemaker/neurostimulator or metal in the\n             head or body;\n\n          -  Pregnant or trying to get pregnant\n\n          -  Failed to respond to an adequate course of electroconvulsive therapy (ECT)\n\n          -  Previous treatment with TMS\n\n          -  Current depressive episode longer than 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900314", 
            "org_study_id": "HUM00053677", 
            "secondary_id": "1R21MH098174-01A1"
        }, 
        "intervention": {
            "arm_group_label": [
                "Active rTMS", 
                "Sham rTMS"
            ], 
            "description": "20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.", 
            "intervention_name": "repetitive Transcranial Magnetic Stimulation (rTMS)", 
            "intervention_type": "Device", 
            "other_name": [
                "TMS", 
                "Neuronetics", 
                "NeuroStar", 
                "Sham treatment"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Major Depression", 
            "Major Depressive Disorder", 
            "TMS", 
            "rTMS"
        ], 
        "lastchanged_date": "October 21, 2013", 
        "link": {
            "description": "U of M Clinical Studies", 
            "url": "http://umclinicalstudies.org/HUM00053677"
        }, 
        "location": {
            "contact": {
                "email": "Psych-rTMS-Study@med.umich.edu", 
                "last_name": "Tessa Abagis", 
                "phone": "734-232-0129"
            }, 
            "contact_backup": {
                "last_name": "Laura M Stchur, LMSW", 
                "phone": "734-936-1323"
            }, 
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan"
            }, 
            "investigator": {
                "last_name": "Stephan F Taylor, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Imaging Biomarkers for TMS Treatment of Depression", 
        "other_outcome": {
            "description": "Primary:  Changes in depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scales (MADRS) Secondary:  changes in depressive symptoms as measured by the 17-item Hamilton Rating Scale for Depression (HRSD33) and the self-rated Quick Inventory of Depressive Symptoms-Self Rated/40 questions(QIDS-SR40]).", 
            "measure": "Changes in depression symptoms", 
            "safety_issue": "No", 
            "time_frame": "baseline and 4 weeks"
        }, 
        "overall_contact": {
            "email": "Psych-rTMS-Study@med.umich.edu", 
            "last_name": "Tessa Abagis", 
            "phone": "734-232-0129"
        }, 
        "overall_contact_backup": {
            "last_name": "Laura M Stchur, LMSW", 
            "phone": "734-936-1323"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan", 
            "last_name": "Stephan F Taylor, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Our primary hypothesis is that rTMS will increase cortical excitability, leading to more efficient cortex manifested as smaller CBF increases in left dorsolateral Prefrontal Cortex (dlPFC) during working memory activation.  Our secondary hypotheses are that rTMS will increase resting CBF in the dlPFC and will induce plastic changes throughout a network of brain regions connected with the dlPFC, including the medial frontal cortex, a region associated with emotion regulation and known to exhibit aberrant function in major depression disorder(MDD).", 
            "measure": "Changes in cerebral blood flow (CBF) as measured by functional Magnetic Resonance Imaging (fMRI).", 
            "safety_issue": "No", 
            "time_frame": "baseline and 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900314"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan", 
            "investigator_full_name": "Stephan Taylor", 
            "investigator_title": "Professor of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "We will test the hypothesis that rTMS will change functional connectivity (fcMRI) between the dlPFC target and ventral networks before and after rTMS treatment.", 
            "measure": "Resting state functional connectivity", 
            "safety_issue": "No", 
            "time_frame": "baseline and 4 weeks"
        }, 
        "source": "University of Michigan", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Mental Health (NIMH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Neuronetics", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Michigan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}